<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35764955</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>30</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1479-5876</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>28</Day></PubDate></JournalIssue><Title>Journal of translational medicine</Title><ISOAbbreviation>J Transl Med</ISOAbbreviation></Journal><ArticleTitle>Oxaloacetate Treatment For Mental And Physical Fatigue In Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long-COVID fatigue patients: a non-randomized controlled clinical trial.</ArticleTitle><Pagination><StartPage>295</StartPage><MedlinePgn>295</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">295</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12967-022-03488-3</ELocationID><Abstract><AbstractText Label="BACKGROUND">There is no approved pharmaceutical intervention for Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS). Fatigue in these patients can last for decades. Long COVID may continue to ME/CFS, and currently, it is estimated that up to 20 million Americans have significant symptoms after COVID, and the most common symptom is fatigue. Anhydrous Enol-Oxaloacetate, (AEO) a nutritional supplement, has been anecdotally reported to relieve physical and mental fatigue and is dimished in ME/CFS patients. Here, we examine the use of higher dosage AEO as a medical food to relieve pathological fatigue.</AbstractText><AbstractText Label="METHODS">ME/CFS and Long-COVID patients were enrolled in an open label dose escalating "Proof of Concept" non-randomized controlled clinical trial with 500&#xa0;mg AEO capsules. Control was provided by a historical ME/CFS fatigue trial and supporting meta-analysis study, which showed average improvement with oral placebo using the Chalder Scale of 5.9% improvement from baseline. At baseline, 73.7% of the ME/CFS patients were women, average age was 47 and length of ME/CFS from diagnosis was 8.9&#xa0;years. The Long-COVID patients were a random group that responded to social media advertising (Face Book) with symptoms for at least 6&#xa0;months. ME/CFS patients were given separate doses of 500&#xa0;mg BID (N&#x2009;=&#x2009;23), 1,000&#xa0;mg BID (N&#x2009;=&#x2009;29) and 1000&#xa0;mg TID (N&#x2009;=&#x2009;24) AEO for six weeks. Long COVID patients were given 500&#xa0;mg AEO BID (N&#x2009;=&#x2009;22) and 1000&#xa0;mg AEO (N&#x2009;=&#x2009;21), again over a six-week period. The main outcome measure was to compare baseline scoring with results at 6&#xa0;weeks with the Chalder Fatigue Score (Likert Scoring) versus historical placebo. The hypothesis being tested was formulated prior to data collection.</AbstractText><AbstractText Label="RESULTS">76 ME/CFS patients (73.7% women, median age of 47) showed an average reduction in fatigue at 6&#xa0;weeks as measured by the "Chalder Fatigue Questionnaire" of 22.5% to 27.9% from baseline (P&#x2009;&lt;&#x2009;0.005) (Likert scoring). Both physical and mental fatigue were significantly improved over baseline and historical placebo. Fatigue amelioration in ME/CFS patients increased in a dose dependent manner from 21.7% for 500&#xa0;mg BID to 27.6% for 1000&#xa0;mg Oxaloacetate BID to 33.3% for 1000&#xa0;mg TID. Long COVID patients' fatigue was significantly reduced by up to 46.8% in 6-weeks.</AbstractText><AbstractText Label="CONCLUSIONS">Significant reductions in physical and metal fatigue for ME/CFS and Long-COVID patients were seen after 6&#xa0;weeks of treatment. As there has been little progress in providing fatigue relief for the millions of ME/CFS and Long COVID patients, anhydrous enol oxaloacetate may bridge this important medical need. Further study of oxaloacetate supplementation for the treatment of ME/CFS and Long COVID is warranted. Trial Registration https://clinicaltrials.gov/ct2/show/NCT04592354 Registered October 19, 2020. 1,000 mg BID Normalized Fatigue Data for Baseline, 2-weeks and 6-weeks evaluated by 3 Validated Fatigue Scoring Questionnaires.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cash</LastName><ForeName>Alan</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1916-960X</Identifier><AffiliationInfo><Affiliation>Terra Biological LLC, 3830 Valley Centre Drive, Ste 705 PMB 561, San Diego, CA, USA. acash@TerraBiological.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaufman</LastName><ForeName>David Lyons</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Center for Complex Diseases, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04592354</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D018848">Controlled Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Transl Med</MedlineTA><NlmUniqueID>101190741</NlmUniqueID><ISSNLinking>1479-5876</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>2F399MM81J</RegistryNumber><NameOfSubstance UI="D062907">Oxaloacetic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015673" MajorTopicYN="Y">Fatigue Syndrome, Chronic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005222" MajorTopicYN="N">Mental Fatigue</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062907" MajorTopicYN="Y">Oxaloacetic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anhydrous enol oxaloacetate</Keyword><Keyword MajorTopicYN="N">COVID fatigue</Keyword><Keyword MajorTopicYN="N">Chronic fatigue syndrome</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">ME/CFS</Keyword><Keyword MajorTopicYN="N">ME/CFS clinical</Keyword><Keyword MajorTopicYN="N">ME/CFS treatment</Keyword><Keyword MajorTopicYN="N">Oxaloacetate</Keyword><Keyword MajorTopicYN="N">Post viral fatigue</Keyword></KeywordList><CoiStatement>Author David Kaufman has no competing interests. Author Alan Cash is an officer in a pharmaceutical company that provided the funding for this clinical trial. Funding was provided by Terra Biological LLC.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>28</Day><Hour>23</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>6</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35764955</ArticleId><ArticleId IdType="pmc">PMC9238249</ArticleId><ArticleId IdType="doi">10.1186/s12967-022-03488-3</ArticleId><ArticleId IdType="pii">10.1186/s12967-022-03488-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Evans WJ, Lambert CP. Physiological basis of fatigue. Am J Phys Med Rehabil. 2007;86(1 Suppl):S29&#x2013;46. doi: 10.1097/PHM.0b013e31802ba53c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PHM.0b013e31802ba53c</ArticleId><ArticleId IdType="pubmed">17370370</ArticleId></ArticleIdList></Reference><Reference><Citation>Lock AM, Bonetti DL, Campbell ADK. The psychological and physiological health effects of fatigue. Occup Med (Lond) 2018;68(8):502&#x2013;511. doi: 10.1093/occmed/kqy109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/occmed/kqy109</ArticleId><ArticleId IdType="pubmed">30445654</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnett R. Fatigue. Lancet. 2005;366(9479):21. doi: 10.1016/S0140-6736(05)66809-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(05)66809-2</ArticleId><ArticleId IdType="pubmed">15993215</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan JJ, Qin Z, Wang PY, et al. Muscle fatigue: general understanding and treatment. Exp Mol Med. 2017;49(10):e384. doi: 10.1038/emm.2017.194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emm.2017.194</ArticleId><ArticleId IdType="pmc">PMC5668469</ArticleId><ArticleId IdType="pubmed">28983090</ArticleId></ArticleIdList></Reference><Reference><Citation>Pennisi M, Malaguarnera G, Di Bartolo G, et al. Decrease in Serum Vitamin D Level of Older Patients with Fatigue. Nutrients. 2019;11(10):2531. doi: 10.3390/nu11102531.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11102531</ArticleId><ArticleId IdType="pmc">PMC6836014</ArticleId><ArticleId IdType="pubmed">31635199</ArticleId></ArticleIdList></Reference><Reference><Citation>Naviaux RK, Naviaux JC, Li K, et al. Metabolic features of chronic fatigue syndrome. Proc Natl Acad Sci USA. 2016;113(37):E5472&#x2013;5480. doi: 10.1073/pnas.1607571113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1607571113</ArticleId><ArticleId IdType="pmc">PMC5027464</ArticleId><ArticleId IdType="pubmed">27573827</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul BD, Lemle MD, Komaroff AL, et al. Redox imbalance links COVID-19 and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Proc Natl Acad Sci USA. 2021;118(34):e2024358118. doi: 10.1073/pnas.2024358118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2024358118</ArticleId><ArticleId IdType="pmc">PMC8403932</ArticleId><ArticleId IdType="pubmed">34400495</ArticleId></ArticleIdList></Reference><Reference><Citation>Komaroff AL, Bateman L. Will COVID-19 lead to myalgic encephalomyelitis/chronic fatigue syndrome? Front Med (Lausanne) 2020;7:606824. doi: 10.3389/fmed.2020.606824.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.606824</ArticleId><ArticleId IdType="pmc">PMC7848220</ArticleId><ArticleId IdType="pubmed">33537329</ArticleId></ArticleIdList></Reference><Reference><Citation>Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309&#x2013;314. doi: 10.1126/science.123.3191.309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.123.3191.309</ArticleId><ArticleId IdType="pubmed">13298683</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornberg MD. The immunologic Warburg effect: Evidence and therapeutic opportunities in autoimmunity. Wiley Interdiscip Rev Syst Biol Med. 2020;12(5):e1486. doi: 10.1002/wsbm.1486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/wsbm.1486</ArticleId><ArticleId IdType="pmc">PMC7507184</ArticleId><ArticleId IdType="pubmed">32105390</ArticleId></ArticleIdList></Reference><Reference><Citation>Icard P, Lincet H, Wu Z, et al. The key role of Warburg effect in SARS-CoV-2 replication and associated inflammatory response. Biochimie. 2020;180:169&#x2013;177. doi: 10.1016/j.biochi.2020.11.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biochi.2020.11.010</ArticleId><ArticleId IdType="pmc">PMC7659517</ArticleId><ArticleId IdType="pubmed">33189832</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawson N, Hsieh CH, March D, et al. Elevated energy production in chronic fatigue syndrome patients. J Nat Sci. 2016;2(10):e221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5065105</ArticleId><ArticleId IdType="pubmed">27747291</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham T, Sjogaard G, Lollgen H, et al. NAD in muscle of man at rest and during exercise. Pflugers Arch. 1978;376(1):35&#x2013;39. doi: 10.1007/BF00585245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00585245</ArticleId><ArticleId IdType="pubmed">212709</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahlin K, Katz A, Henriksson J. Redox state and lactate accumulation in human skeletal muscle during dynamic exercise. Biochem J. 1987;245(2):551&#x2013;556. doi: 10.1042/bj2450551.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/bj2450551</ArticleId><ArticleId IdType="pmc">PMC1148157</ArticleId><ArticleId IdType="pubmed">3663177</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweetman E, Kleffmann T, Edgar C, et al. A SWATH-MS analysis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome peripheral blood mononuclear cell proteomes reveals mitochondrial dysfunction. J Transl Med. 2020;18(1):365. doi: 10.1186/s12967-020-02533-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-020-02533-3</ArticleId><ArticleId IdType="pmc">PMC7512220</ArticleId><ArticleId IdType="pubmed">32972442</ArticleId></ArticleIdList></Reference><Reference><Citation>Afrin LB, Weinstock LB, Molderings GJ. Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome. Int J Infect Dis. 2020;100:327&#x2013;332. doi: 10.1016/j.ijid.2020.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.09.016</ArticleId><ArticleId IdType="pmc">PMC7529115</ArticleId><ArticleId IdType="pubmed">32920235</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta SC, Kim JH, Kannappan R, et al. Role of nuclear factor kappaB-mediated inflammatory pathways in cancer-related symptoms and their regulation by nutritional agents. Exp Biol Med (Maywood) 2011;236(6):658&#x2013;671. doi: 10.1258/ebm.2011.011028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1258/ebm.2011.011028</ArticleId><ArticleId IdType="pmc">PMC3141285</ArticleId><ArticleId IdType="pubmed">21565893</ArticleId></ArticleIdList></Reference><Reference><Citation>Bower JE, Ganz PA, Irwin MR, et al. Fatigue and gene expression in human leukocytes: increased NF-kappaB and decreased glucocorticoid signaling in breast cancer survivors with persistent fatigue. Brain Behav Immun. 2011;25(1):147&#x2013;150. doi: 10.1016/j.bbi.2010.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2010.09.010</ArticleId><ArticleId IdType="pmc">PMC3603145</ArticleId><ArticleId IdType="pubmed">20854893</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris G, Maes M. Increased nuclear factor-kappaB and loss of p53 are key mechanisms in Myalgic Encephalomyelitis/chronic fatigue syndrome (ME/CFS) Med Hypotheses. 2012;79(5):607&#x2013;613. doi: 10.1016/j.mehy.2012.07.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2012.07.034</ArticleId><ArticleId IdType="pubmed">22951418</ArticleId></ArticleIdList></Reference><Reference><Citation>Filler K, Lyon D, Bennett J, et al. Association of mitochondrial dysfunction and fatigue: a review of the literature. BBA Clin. 2014;1:12&#x2013;23. doi: 10.1016/j.bbacli.2014.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbacli.2014.04.001</ArticleId><ArticleId IdType="pmc">PMC4136529</ArticleId><ArticleId IdType="pubmed">25147756</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown AE, Jones DE, Walker M, et al. Abnormalities of AMPK activation and glucose uptake in cultured skeletal muscle cells from individuals with chronic fatigue syndrome. PLoS ONE. 2015;10(4):e0122982. doi: 10.1371/journal.pone.0122982.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0122982</ArticleId><ArticleId IdType="pmc">PMC4383615</ArticleId><ArticleId IdType="pubmed">25836975</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisicaro F, Di Napoli M, Liberto A, et al. Neurological sequelae in patients with COVID-19: a histopathological perspective. Int J Environ Res Public Health. 2021;18(4):1415. doi: 10.3390/ijerph18041415.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph18041415</ArticleId><ArticleId IdType="pmc">PMC7913756</ArticleId><ArticleId IdType="pubmed">33546463</ArticleId></ArticleIdList></Reference><Reference><Citation>Nogueira L. Acute oxaloacetate exposure enhances resistance to fatigue in in vitro mouse soleus muscle. FASEB J. 2011 doi: 10.1096/fasebj.25.1_supplement.1104.5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fasebj.25.1_supplement.1104.5</ArticleId></ArticleIdList></Reference><Reference><Citation>Germain A, Ruppert D, Levine SM, et al. Metabolic profiling of a myalgic encephalomyelitis/chronic fatigue syndrome discovery cohort reveals disturbances in fatty acid and lipid metabolism. Mol Biosyst. 2017;13(2):371&#x2013;379. doi: 10.1039/C6MB00600K.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C6MB00600K</ArticleId><ArticleId IdType="pmc">PMC5365380</ArticleId><ArticleId IdType="pubmed">28059425</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med. 1994;121(12):953&#x2013;959. doi: 10.7326/0003-4819-121-12-199412150-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-121-12-199412150-00009</ArticleId><ArticleId IdType="pubmed">7978722</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalder T, Berelowitz G, Pawlikowska T, et al. Development of a fatigue scale. J Psychosom Res. 1993;37(2):147&#x2013;153. doi: 10.1016/0022-3999(93)90081-P.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-3999(93)90081-P</ArticleId><ArticleId IdType="pubmed">8463991</ArticleId></ArticleIdList></Reference><Reference><Citation>Krupp LB, LaRocca NG, Muir-Nash J, et al. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10):1121&#x2013;1123. doi: 10.1001/archneur.1989.00520460115022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1989.00520460115022</ArticleId><ArticleId IdType="pubmed">2803071</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang M, Keller S, Lin JS. Psychometric properties of the PROMIS((R)) Fatigue Short Form 7a among adults with myalgic encephalomyelitis/chronic fatigue syndrome. Qual Life Res. 2019;28(12):3375&#x2013;3384. doi: 10.1007/s11136-019-02289-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11136-019-02289-4</ArticleId><ArticleId IdType="pubmed">31506915</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho HJ, Hotopf M, Wessely S. The placebo response in the treatment of chronic fatigue syndrome: a systematic review and meta-analysis. Psychosom Med. 2005;67(2):301&#x2013;313. doi: 10.1097/01.psy.0000156969.76986.e0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.psy.0000156969.76986.e0</ArticleId><ArticleId IdType="pubmed">15784798</ArticleId></ArticleIdList></Reference><Reference><Citation>Ijare O, Conway D, Cash A, et al. CBMT-49. oxaloacetate alters glucose metabolism in glioblastoma 13C isotopomer study. Neuro-Oncology. 2019;21(Supplement_6):vi43&#x2013;vi44. doi: 10.1093/neuonc/noz175.171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/neuonc/noz175.171</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris G, Maes M. Oxidative and Nitrosative Stress and immune-inflammatory pathways in patients with Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS) Curr Neuropharmacol. 2014;12(2):168&#x2013;185. doi: 10.2174/1570159X11666131120224653.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570159X11666131120224653</ArticleId><ArticleId IdType="pmc">PMC3964747</ArticleId><ArticleId IdType="pubmed">24669210</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkins HM, Harris JL, Carl SM, et al. Oxaloacetate activates brain mitochondrial biogenesis, enhances the insulin pathway, reduces inflammation and stimulates neurogenesis. Hum Mol Genet. 2014;23(24):6528&#x2013;6541. doi: 10.1093/hmg/ddu371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu371</ArticleId><ArticleId IdType="pmc">PMC4271074</ArticleId><ArticleId IdType="pubmed">25027327</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams DS, Cash A, Hamadani L, et al. Oxaloacetate supplementation increases lifespan in Caenorhabditis elegans through an AMPK/FOXO-dependent pathway. Aging Cell. 2009;8(6):765&#x2013;768. doi: 10.1111/j.1474-9726.2009.00527.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1474-9726.2009.00527.x</ArticleId><ArticleId IdType="pmc">PMC2988682</ArticleId><ArticleId IdType="pubmed">19793063</ArticleId></ArticleIdList></Reference><Reference><Citation>Haslam JM, Krebs HA. The permeability of mitochondria to oxaloacetate and malate. Biochem J. 1968;107(5):659&#x2013;667. doi: 10.1042/bj1070659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/bj1070659</ArticleId><ArticleId IdType="pmc">PMC1198718</ArticleId><ArticleId IdType="pubmed">16742587</ArticleId></ArticleIdList></Reference><Reference><Citation>Booth NE, Myhill S, McLaren-Howard J. Mitochondrial dysfunction and the pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Int J Clin Exp Med. 2012;5(3):208&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3403556</ArticleId><ArticleId IdType="pubmed">22837795</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkins HM, Koppel S, Carl SM, et al. Oxaloacetate enhances neuronal cell bioenergetic fluxes and infrastructure. J Neurochem. 2016 doi: 10.1111/jnc.13545.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13545</ArticleId><ArticleId IdType="pmc">PMC5482267</ArticleId><ArticleId IdType="pubmed">26811028</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown AE, Dibnah B, Fisher E, 2018. Pharmacological activation of AMPK and glucose uptake in cultured human skeletal muscle cells from patients with ME/CFS. Biosci Rep.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BSR20180242</ArticleId><ArticleId IdType="pmc">PMC5938427</ArticleId><ArticleId IdType="pubmed">29654166</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshikawa K. Studies on the anti-diabetic effect of sodium oxaloacetate. Tohoku J Exp Med. 1968;96(2):127&#x2013;141. doi: 10.1620/tjem.96.127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1620/tjem.96.127</ArticleId><ArticleId IdType="pubmed">4884771</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidoni ED, Choi IY, Lee P, et al. Safety and target engagement profile of two oxaloacetate doses in Alzheimer's patients. Alzheimers Dement. 2020 doi: 10.1002/alz.12156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12156</ArticleId><ArticleId IdType="pmc">PMC8084114</ArticleId><ArticleId IdType="pubmed">32715609</ArticleId></ArticleIdList></Reference><Reference><Citation>Desagher S, Glowinski J, Premont J. Pyruvate protects neurons against hydrogen peroxide-induced toxicity. J Neurosci. 1997;17(23):9060&#x2013;9067. doi: 10.1523/JNEUROSCI.17-23-09060.1997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.17-23-09060.1997</ArticleId><ArticleId IdType="pmc">PMC6573585</ArticleId><ArticleId IdType="pubmed">9364052</ArticleId></ArticleIdList></Reference><Reference><Citation>Puntel RL, Nogueira CW, Rocha JB. Krebs cycle intermediates modulate thiobarbituric acid reactive species (TBARS) production in rat brain in vitro. Neurochem Res. 2005;30(2):225&#x2013;235. doi: 10.1007/s11064-004-2445-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-004-2445-7</ArticleId><ArticleId IdType="pubmed">15895826</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto HA, Mohanan PV. Effect of alpha-ketoglutarate and oxaloacetate on brain mitochondrial DNA damage and seizures induced by kainic acid in mice. Toxicol Lett. 2003;143(2):115&#x2013;122. doi: 10.1016/S0378-4274(03)00114-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0378-4274(03)00114-0</ArticleId><ArticleId IdType="pubmed">12749815</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>